Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status.

ABSTRACT:

Background

Patients with non-small cell lung cancer (NSCLC) treated in real-world practice typically have worse performance status (PS) compared with clinical trial patients, and the effectiveness of immunotherapy in this population in unknown. In this study, we assessed the effectiveness of standard of care immunotherapy for the first-line treatment of stage IV patients with NSCLC with Eastern Cooperative Oncology Group (ECOG) PS greater than or equal to 2.

Methods

We selected ECOG PS greater than or equal to 2 patients from real-world oncology data from a deidentified database and included them if they were diagnosed with stage IV NSCLC and had documented Programmed death-ligand 1 [PD-(L)1] expression greater than 0. Patients with tumor PD-(L)1 expression of at least 50% t

SUBMITTER: Veluswamy R 

PROVIDER: S-EPMC8921740 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature